Deepa Kannaditharayil, MD
Neurology · Fremont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Offices
- 2
Offices
2 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: San Ramon Regional Medical Center · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kannaditharayil’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A143758 · Current
Licensed to practise in California · since 2016 · expires 2028-05-31 · Calicut University Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- San Ramon Regional Medical CenterSan Ramon, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 3 of 5 · 65% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for San Ramon Regional Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 0 better, 7 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.94 (0 to 1.97) · 507 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.83 (0.44 to 1.22) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.1 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 87 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.2 · 195 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.7 · 284 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 63 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,118 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 2,515 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.08 to 0.49) · 2,618 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.62 (1.26 to 5.98) · 588 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0 to 3.14) · 282 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.34 (0.72 to 3.97) · 598 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.12 (0.84 to 15.4) · 258 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.08 (0.25 to 7.91) · 225 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.02 (0.52 to 3.52) · 241 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.29) · 2,110 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 73 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.553 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.104 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 84 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 186 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 39.6 · 79 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -10.3 · 227 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -5.2 · 305 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 314 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.9 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 37 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.4 to 17.3) · 86 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 256 cases | No different | Jan 2024 – Dec 2024 |
What patients said (642 patients answered, 25% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 65% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 65% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$66,914
Medicare paid this office $66,914 for 285 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Botox | 13 | $15,286 | None |
| Return visit (30+ min) | 158 | $12,983 | $76 |
| New patient visit (60+ min) | 50 | $10,071 | $201 |
| Long return visit (40+ min) | 49 | $7,317 | $133 |
| New patient visit (45+ min) | 39 | $5,745 | $147 |
See all 9 services
| Botox | 13 | $15,286 | None |
| Return visit (30+ min) | 158 | $12,983 | $76 |
| New patient visit (60+ min) | 50 | $10,071 | $201 |
| Long return visit (40+ min) | 49 | $7,317 | $133 |
| New patient visit (45+ min) | 39 | $5,745 | $147 |
| Nerve test | 14 | $3,042 | $217 |
| Muscle electrical test | 19 | $3,023 | $92 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 13 | $1,973 | $116 |
| Muscle electrical test | 14 | $1,041 | $58 |
Who their Medicare patients are
285 Original Medicare patients in 2024. Average age 74 · Under 65 12% · 85 and older 13% · Women 60% · Also on Medicaid 23% · Health risk score 1.35. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 71% · Diabetes 31% · Depression 30% · Chronic kidney disease 28% · Coronary heart disease 26% · Dementia 20% · Atrial fibrillation 18% · Heart failure 15% · Stroke 14% · COPD 12% · Cancer 9%.
The office billed $272,745, Medicare allowed $93,656 and paid $66,914; for 5,050 services of 22 kinds; $15,286 of it was for drugs given in the office and $51,628 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 285 | 5,050 | 74 | 1.35 | $272,745 | $66,914 |
| 2023 | 319 | 7,773 | 72 | 1.35 | $547,768 | $126,833 |
| 2022 | 330 | 7,351 | 73 | 1.49 | $521,548 | $127,277 |
| 2021 | 318 | 9,195 | 73 | 1.48 | $495,768 | $133,259 |
| 2020 | 336 | 4,606 | 72 | 1.85 | $336,230 | $83,909 |
| 2019 | 299 | 804 | 72 | 2.59 | $303,171 | $50,785 |
| 2018 | 187 | 248 | 71 | 2.88 | $232,941 | $33,493 |
| 2017 | 121 | 153 | 70 | 3.12 | $165,414 | $21,393 |
| 2016 | 187 | 241 | 73 | 3.03 | $215,213 | $33,422 |
| 2015 | 196 | 253 | 73 | 3.11 | $142,408 | $37,076 |
| 2014 | 107 | 156 | 69 | 2.80 | $68,390 | $20,933 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Botox | 11 | $32,789 | None |
| Return visit (30+ min) | 197 | $28,910 | $90 |
| Long return visit (40+ min) | 74 | $14,200 | $135 |
| New patient visit (60+ min) | 50 | $8,664 | $173 |
| New patient visit (45+ min) | 51 | $6,364 | $125 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 11 | $4,342 | $124 |
| Nerve test | 16 | $3,863 | $241 |
| Measurement of brain wave activity (eeg), awake and drowsy | 11 | $3,661 | $333 |
| Muscle electrical test | 23 | $3,003 | $83 |
| Muscle electrical test | 30 | $2,422 | $49 |
| Nerve test | 13 | $1,205 | $93 |
2022: 15 services
| Botox | 12 | $30,246 | None |
| Long return visit (40+ min) | 156 | $27,741 | $128 |
| Return visit (30+ min) | 137 | $18,711 | $98 |
| New patient visit (60+ min) | 69 | $11,146 | $162 |
| Nerve test | 19 | $4,112 | $206 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 11 | $4,030 | $122 |
| Measurement of brain wave activity (eeg), awake and drowsy | 12 | $3,939 | $328 |
| Nerve test | 15 | $3,582 | $239 |
| New patient visit (45+ min) | 26 | $3,187 | $123 |
| Muscle electrical test | 31 | $2,916 | $56 |
| Muscle electrical test | 20 | $2,592 | $86 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 11 | $1,922 | $49 |
| Nerve test | 15 | $1,754 | $117 |
| Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | 11 | $1,748 | $45 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 46 | $1,483 | $26 |
2021: 13 services
| Botox | 14 | $40,042 | None |
| Long return visit (40+ min) | 142 | $30,385 | $137 |
| New patient visit (60+ min) | 96 | $16,013 | $167 |
| Return visit (30+ min) | 108 | $12,862 | $98 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 14 | $5,237 | $125 |
| Nerve test | 17 | $4,223 | $248 |
| Muscle electrical test | 24 | $3,700 | $86 |
| Injection of anesthetic agent and/or steroid into face nerve | 12 | $3,273 | $106 |
| Nerve test | 15 | $3,010 | $201 |
| Measurement of brain wave activity (eeg), awake and drowsy | 12 | $2,807 | $234 |
| Muscle electrical test | 27 | $2,667 | $57 |
| New patient visit (45+ min) | 17 | $2,146 | $126 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 25 | $1,035 | $27 |
2020: 12 services
| Long return visit (40+ min) | 94 | $13,715 | $114 |
| New patient visit (60+ min) | 81 | $12,965 | $160 |
| Return visit (30+ min) | 83 | $7,236 | $70 |
| New patient visit (45+ min) | 52 | $5,506 | $106 |
| Injection of anesthetic agent and/or steroid into face nerve | 13 | $3,845 | $99 |
| Measurement of brain wave activity (eeg), awake and drowsy | 52 | $2,392 | $44 |
| Muscle electrical test | 27 | $2,021 | $53 |
| Short return visit (20+ min) | 21 | $1,318 | $57 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,083 | $90 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $925 | $62 |
| Measurement of brain wave activity (eeg), awake and drowsy | 13 | $581 | $45 |
| Telephone medical discussion with physician, 5-10 minutes | 14 | $526 | $38 |
2019: 10 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 114 | $20,599 | $181 |
| New patient visit (45+ min) | 35 | $4,380 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $4,151 | $92 |
| Return visit (30+ min) | 42 | $4,142 | $88 |
| New patient visit (60+ min) | 22 | $3,693 | $168 |
| Emergency department visit with high level of medical decision making | 12 | $1,568 | $131 |
| Emergency department visit with moderate level of medical decision making | 14 | $1,502 | $107 |
| Return visit (30+ min) | 12 | $1,167 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $924 | $66 |
| Measurement of brain wave activity (eeg), awake and drowsy | 19 | $904 | $48 |
2018: 5 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 99 | $18,564 | $184 |
| Emergency department visit with high level of medical decision making | 28 | $4,372 | $151 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $4,056 | $94 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,752 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $1,724 | $66 |
2017: 4 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 80 | $14,692 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,087 | $95 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,628 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $981 | $65 |
2016: 4 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 120 | $22,167 | $183 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $3,864 | $94 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,500 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $1,952 | $65 |
2015: 4 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 144 | $27,157 | $185 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $5,304 | $95 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,880 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $1,505 | $65 |
2014: 4 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 73 | $13,579 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $3,471 | $91 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,343 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $892 | $64 |
Medicaid work
$939 in 2024
Medicaid paid $939 for 30 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 30 | $939 |
| 2024 | 30 | 1 | 16 | $939 |
| 2023 | 27 | 1 | 14 | $1,225 |
| 2019 | 27 | 1 | 13 | $4,927 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 27 | $1,225 |
2019
| 1ST HOSP IP/OBS HIGH 75 | 27 | $4,927 |
Drugs they prescribed that Part D paid
$179,871
Pharmacies billed $179,871 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,125 generic and fewer than 11 brand-name prescriptions · $179,871 in drug cost · 32 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Nurtec Odt | 25 | $44,164 | $1,767 |
| Ubrelvy | 22 | $22,310 | $1,014 |
| Ajovy | 16 | $15,371 | $961 |
| Memantine | 147 | $3,251 | $22 |
| Levetiracetam | 101 | $2,820 | $28 |
See all 27 drugs
| Nurtec Odt | 25 | $44,164 | $1,767 |
| Ubrelvy | 22 | $22,310 | $1,014 |
| Ajovy | 16 | $15,371 | $961 |
| Memantine | 147 | $3,251 | $22 |
| Levetiracetam | 101 | $2,820 | $28 |
| Gabapentin | 120 | $2,309 | $19 |
| Carbidopa-Levodopa | 57 | $1,410 | $25 |
| Nortriptyline | 57 | $1,136 | $20 |
| Divalproex | 32 | $1,106 | $35 |
| Lacosamide | 27 | $1,057 | $39 |
| Donepezil | 120 | $999 | $8 |
| Rivastigmine | 18 | $691 | $38 |
| Carbamazepine | 11 | $638 | $58 |
| Pyridostigmine | 13 | $508 | $39 |
| Primidone | 14 | $482 | $34 |
| Topiramate | 26 | $381 | $15 |
| Duloxetine | 18 | $372 | $21 |
| Amitriptyline | 31 | $351 | $11 |
| Pregabalin | 22 | $318 | $14 |
| Quetiapine | 29 | $315 | $11 |
| Rizatriptan | 17 | $297 | $17 |
| Phenytoin Sodium Extended | 17 | $258 | $15 |
| Modafinil | 12 | $253 | $21 |
| Sumatriptan | 42 | $216 | $5 |
| Cyclobenzaprine | 12 | $179 | $15 |
| Propranolol | 22 | $125 | $6 |
| Meclizine | 16 | $122 | $8 |
Year by year
| 2024 | 1,230 | 269 | None | None | $179,871 |
| 2023 | 1,646 | 259 | 1% (22) | None | $470,048 |
| 2022 | 1,494 | 225 | None | 12% | $518,786 |
| 2021 | 1,336 | 220 | None | 16% | $578,380 |
| 2020 | 1,194 | 259 | 1% (14) | None | $662,940 |
| 2019 | 214 | 84 | None | 11% | $26,795 |
| 2018 | 65 | 15 | 0% (0) | None | $7,235 |
| 2017 | 34 | None | 0% (0) | 0% | $1,684 |
| 2016 | 26 | None | 0% (0) | 0% | $274 |
| 2015 | 76 | 17 | None | None | $1,057 |
| 2014 | 11 | None | None | 0% | $64 |
| 2013 | 29 | None | 0% (0) | 0% | $439 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 30 drugs
| Nurtec Odt | None | 29 | $34,604 | $1,193 |
| Ubrelvy | None | 31 | $32,635 | $1,053 |
| Emgality | Migraine | 24 | $26,956 | $1,123 |
| Glatopa | None | 12 | $22,321 | $1,860 |
| Briviact | None | 11 | $21,630 | $1,966 |
| Nuedexta | None | 11 | $15,776 | $1,434 |
| Ajovy | None | 12 | $9,052 | $754 |
| Lacosamide | None | 45 | $5,361 | $119 |
| Gabapentin | None | 167 | $5,022 | $30 |
| Carbidopa-Levodopa | None | 76 | $4,529 | $60 |
| Memantine | None | 142 | $3,680 | $26 |
| Nortriptyline | None | 95 | $3,349 | $35 |
| Levetiracetam | None | 122 | $2,925 | $24 |
| Donepezil | None | 150 | $1,740 | $12 |
| Primidone | None | 24 | $1,633 | $68 |
| Topiramate | None | 63 | $1,524 | $24 |
| Duloxetine | None | 34 | $1,387 | $41 |
| Divalproex | None | 40 | $1,316 | $33 |
| Rivastigmine | None | 18 | $1,010 | $56 |
| Propranolol | None | 35 | $910 | $26 |
| Amitriptyline | None | 46 | $881 | $19 |
| Phenytoin Sodium Extended | None | 22 | $806 | $37 |
| Sumatriptan | None | 46 | $801 | $17 |
| Rizatriptan | None | 34 | $733 | $22 |
| Lamotrigine | None | 20 | $699 | $35 |
| Quetiapine | None | 50 | $549 | $11 |
| Pregabalin | None | 29 | $347 | $12 |
| Butalb-Acetaminoph-Caff-Codein | None | 15 | $306 | $20 |
| Venlafaxine Hcl Er | None | 12 | $122 | $10 |
| Lorazepam | None | 18 | $22 | $1 |
2022: 31 drugs
| Copaxone | 16 | $104,751 | $6,547 |
| Nurtec Odt | 28 | $34,936 | $1,248 |
| Ubrelvy | 33 | $33,849 | $1,026 |
| Nuedexta | 12 | $18,216 | $1,518 |
| Vimpat | 11 | $9,370 | $852 |
| Ajovy | 11 | $8,197 | $745 |
| Memantine | 105 | $4,532 | $43 |
| Duloxetine | 55 | $4,160 | $76 |
| Lacosamide | 15 | $4,153 | $277 |
| Levetiracetam | 100 | $3,773 | $38 |
| Gabapentin | 156 | $3,708 | $24 |
| Nortriptyline | 160 | $3,502 | $22 |
| Carbidopa-Levodopa | 88 | $2,621 | $30 |
| Donepezil | 116 | $1,071 | $9 |
| Topiramate | 44 | $1,046 | $24 |
| Amitriptyline | 53 | $1,020 | $19 |
| Primidone | 27 | $967 | $36 |
| Pyridostigmine | 12 | $953 | $79 |
| Rivastigmine | 21 | $953 | $45 |
| Phenytoin Sodium Extended | 24 | $925 | $39 |
| Divalproex | 30 | $887 | $30 |
| Pregabalin | 38 | $867 | $23 |
| Propranolol | 30 | $775 | $26 |
| Rizatriptan | 34 | $627 | $18 |
| Sumatriptan | 38 | $509 | $13 |
| Lamotrigine | 11 | $248 | $23 |
| Meclizine | 15 | $193 | $13 |
| Quetiapine | 12 | $159 | $13 |
| Prednisone | 11 | $39 | $4 |
| Single Use Swab | 12 | $26 | $2 |
| Lorazepam | 11 | $11 | $1 |
2021: 30 drugs
| Copaxone | None | 19 | $123,360 | $6,493 |
| Rebif Rebidose | None | 11 | $104,260 | $9,478 |
| Nuplazid | Parkinson's psychosis | 13 | $52,769 | $4,059 |
| Ubrelvy | None | 32 | $30,898 | $966 |
| Nuedexta | None | 11 | $15,512 | $1,410 |
| Nurtec Odt | None | 13 | $12,290 | $945 |
| Vimpat | None | 15 | $9,386 | $626 |
| Memantine | None | 146 | $5,247 | $36 |
| Carbidopa-Levodopa | None | 61 | $4,682 | $77 |
| Gabapentin | None | 163 | $4,447 | $27 |
| Levetiracetam | None | 82 | $3,244 | $40 |
| Depakote Er | None | 12 | $2,415 | $201 |
| Nortriptyline | None | 123 | $1,976 | $16 |
| Pregabalin | None | 27 | $1,805 | $67 |
| Duloxetine | None | 40 | $1,498 | $37 |
| Donepezil | None | 136 | $1,289 | $9 |
| Depakote | None | 12 | $1,143 | $95 |
| Primidone | None | 20 | $909 | $45 |
| Rivastigmine | None | 16 | $656 | $41 |
| Pyridostigmine | None | 20 | $618 | $31 |
| Propranolol Hcl Er | None | 17 | $564 | $33 |
| Propranolol | None | 12 | $513 | $43 |
| Topiramate | None | 33 | $469 | $14 |
| Sumatriptan | None | 40 | $460 | $11 |
| Amitriptyline | None | 19 | $426 | $22 |
| Lasix | None | 12 | $354 | $30 |
| Rizatriptan | None | 11 | $353 | $32 |
| Meclizine | None | 11 | $228 | $21 |
| Prednisone | None | 12 | $30 | $3 |
| Lorazepam | None | 18 | $28 | $2 |
2020: 30 drugs
| Copaxone | None | 21 | $146,228 | $6,963 |
| Gilenya | None | 15 | $137,217 | $9,148 |
| Vimpat | None | 28 | $22,762 | $813 |
| Ubrelvy | None | 23 | $19,666 | $855 |
| Briviact | None | 11 | $17,971 | $1,634 |
| Ajovy | None | 21 | $13,848 | $659 |
| Aimovig | Migraine | 14 | $8,879 | $634 |
| Rasagiline Mesylate | None | 16 | $7,992 | $500 |
| Carbidopa-Levodopa | None | 58 | $3,665 | $63 |
| Gabapentin | None | 139 | $3,524 | $25 |
| Rivastigmine | None | 13 | $3,406 | $262 |
| Memantine | None | 57 | $2,550 | $45 |
| Levetiracetam | None | 73 | $2,474 | $34 |
| Pregabalin | None | 31 | $1,667 | $54 |
| Duloxetine | None | 30 | $1,655 | $55 |
| Divalproex Sodium Er | None | 18 | $1,571 | $87 |
| Nortriptyline | None | 62 | $1,240 | $20 |
| Sumatriptan | None | 49 | $970 | $20 |
| Topiramate | None | 41 | $816 | $20 |
| Divalproex | None | 14 | $785 | $56 |
| Propranolol | None | 21 | $666 | $32 |
| Donepezil | None | 63 | $553 | $9 |
| Propranolol Hcl Er | None | 11 | $524 | $48 |
| Amitriptyline | None | 26 | $508 | $20 |
| Lamotrigine | None | 14 | $383 | $27 |
| Primidone | None | 15 | $359 | $24 |
| Prochlorperazine Maleate | None | 14 | $322 | $23 |
| Quetiapine | None | 11 | $119 | $11 |
| Prednisone | None | 12 | $38 | $3 |
| Lorazepam | None | 18 | $36 | $2 |
2019: 5 drugs
| Lyrica | 13 | $9,000 | $692 |
| Gabapentin | 71 | $1,781 | $25 |
| Propranolol | 11 | $396 | $36 |
| Donepezil | 17 | $120 | $7 |
| Nortriptyline | 13 | $119 | $9 |
2018: 1 drug
| Gabapentin | 35 | $629 | $18 |
2017: 1 drug
| Gabapentin | 18 | $171 | $9 |
2016: 1 drug
| Gabapentin | 14 | $111 | $8 |
2015: 2 drugs
| Levetiracetam | 13 | $279 | $21 |
| Gabapentin | 16 | $134 | $8 |
Money from drug and device companies
$51 in 2025
| 2025 | 2 | 3 | None | $51 |
| 2024 | 8 | 15 | None | $413 |
| 2023 | 10 | 16 | None | $332 |
| 2021 | 1 | 1 | None | $26 |
| 2020 | 6 | 9 | None | $220 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
See all 3 published payments
| Ucb | Education · 2025-12-15 | Zilbrysq | $18 |
| Abbvie | Meals · 2025-10-17 | Botox | $19 |
| Ucb | Education · 2025-04-11 | Rystiggo | $15 |
See earlier years (2024, 2023, 2021, 2020)
2024: $413
| Eisai | Leqembi | $118 | 2 payments
|
| SK Life Science | None | $81 | 3 payments
|
| Abbvie | Botox | $63 | 3 payments
|
| Alexion Pharmaceuticals | Soliris | $62 | 3 payments
|
| Novartis Pharmaceuticals | Kesimpta | $28 | 1 payment
|
| Biogen | Tysabri | $24 | 1 payment
|
| Genentech USA | Enspryng | $23 | 1 payment
|
| Ucb | Rystiggo | $14 | 1 payment
|
2023: $332
| Pfizer | Nurtec Odt | $56 | 3 payments
|
| Novartis Pharmaceuticals | Kesimpta | $51 | 3 payments
|
| Abbvie | Ubrelvy | $50 | 2 payments
|
| Eisai | Leqembi | $49 | 2 payments
|
| Argenx US | Vyvgart | $28 | 1 payment
|
| Genentech | Ocrevus | $25 | 1 payment
|
| Mitsubishi Tanabe Pharma America | Radicava | $21 | 1 payment
|
| Genentech USA | Enspryng | $20 | 1 payment
|
| Acorda Therapeutics | Inbrija | $16 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $16 | 1 payment
|
2021: $26
| Biohaven Pharmaceuticals | Nurtec Odt | $26 | 1 payment
|
2020: $220
| Ucb | Briviact | $84 | 3 payments
|
| Avanir Pharmaceuticals | Nuedexta | $49 | 2 payments
|
| Biogen | Tysabri | $24 | 1 payment
|
| Lilly USA | Reyvow | $24 | 1 payment
|
| Novartis Pharmaceuticals | Kesimpta | $23 | 1 payment
|
| Allergan | Botox | $17 | 1 payment
|
Professional record
- NPI
- 1649508318
- Licence
- CA A143758California A143758: Current · expires 2028-05-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 10470 Old Placerville Rd Ste 100, Sacramento, CA, 95827
- NPI first listed
- 2009-11-18
- NPI last updated
- 2019-09-09
This is when the NPI record was last certified, not a medical board exam.